EC Number   |
Expression |
Reference |
|---|
   2.7.11.18 | down |
0.1 nM androgen R1881 causes a progressive decrease in MLCK mRNA levels which decreases by 70% and 90%, respectively, at 24 and 48 h |
709713 |
| 2.7.11.18 | down |
rebeccamycin mediates reduction in enzyme production |
760849 |
| 2.7.11.18 | more |
interferon gamma does not upregulate isoform MLCK1 transcript |
761603 |
| 2.7.11.18 | up |
10 ng/ml tumour necrosis factor-alpha causes a significant increase of myosin light chain kinase gene activity, tumour necrosis factor-alpha causes an increase in nuclear factor-kappaB to the nuclear factor-kappaB1 binding motif which presumably leads to the activation of MLCK promoter |
709236 |
| 2.7.11.18 | up |
breast cancer cells transiently activate endothelial MLCK at tumor invasion sites |
709225 |
| 2.7.11.18 | up |
expression of myosin light chain kinase protein is rapidly increased by angiotensin II |
707035 |
| 2.7.11.18 | up |
Lactobacillus rhamnosus alleviates intestinal barrier dysfunction in part by increasing expression of myosin light-chain kinase in vivo |
709287 |
| 2.7.11.18 | up |
MLCK expression is significantly up-regulated after controlled cortical impact with a maximum 12 h post-injury |
709602 |
| 2.7.11.18 | up |
severe burn injury increases intestinal MLCK protein levels 3.6fold after 2h in animals resuscitated with normal saline |
709732 |
| 2.7.11.18 | up |
the expression level of the splice variant MLCK1 is significantly increased in actively inflamed tissues of the Crohn's disease and ulcerative colitis patient samples. The splice variant MLCK1 is overexpressed in colonic biopsy specimens of inflammatory bowel disease patients. Treatment with low-dose cytokines tumor necrosis factor-like 1A |
761603 |
